EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Cost-Effectiveness of an Artificial Intelligence-Based Population-Wide Screening Program for Primary Open-Angle Glaucoma in The Netherlands

Bart-Jan Boverhof, Isaac Corro Ramos, Koen A Vermeer, Victor A de Vries, Caroline C W Klaver, Wishal D Ramdas, Hans G Lemij, Maureen Rutten-van Mölken

Value in Health · 2025-09 · 28 (9) · 1317-1326

DOI: 10.1016/j.jval.2025.06.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2025-09. Verfasst von Bart-Jan Boverhof und 7 weiteren Autor:innen. Beteiligte Einrichtung: Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands. Electronic address: boverhof@eshpm.eur.nl. Hauptthemen laut MEDLINE: Glaucoma, Open-Angle, Artificial Intelligence, Mass Screening. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Oogfonds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Population-wide screening for primary open-angle glaucoma (glaucoma) is typically not cost-effective because of low prevalence and high costs. We evaluated the cost-effectiveness of repeated artificial intelligence (AI)-based glaucoma screening using fundus photos in the Dutch population aged 50 to 75, compared with opportunistic case finding. METHODS: We developed a health-economic model consisting of a decision tree for screening simulation and a Markov model for disease progression and treatment effects. In AI screening, the population is invited every 5 years for fundus photography in primary care labs, followed by AI triage. Positive cases undergo ophthalmological evaluation. Model inputs included screening repetitions, AI sensitivity (85%), specificity (95%), screening compliance (50%), referral compliance (60%), and glaucoma progression probabilities, based on AI development data, a Dutch cohort, expert opinions, and literature. We performed analyses from societal and healthcare perspectives over a lifetime. RESULTS: AI screening identified glaucoma earlier than opportunistic methods, detecting 1.60 times more cases and reducing visual impairment by 0.8 months per invited individual. Societal perspective analysis indicated a gain of 0.014 quality-adjusted life-years and an incremental cost of €284 per individual, resulting in an incremental cost-effectiveness ratio of €19 311, with a 51.2% probability of being below the €20 000 threshold. Outcomes were most sensitive to glaucoma progression rates, utilities, and visual impairment costs. CONCLUSIONS: AI-based glaucoma screening in The Netherlands could cost-effectively improve early detection and reduce visual impairment burden. Further research should focus on reducing uncertainty regarding disease progression rates and impairment-related costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glaucoma, Open-AngleArtificial IntelligenceMass ScreeningHumansCost-Benefit AnalysisNetherlandsMiddle AgedAgedMarkov ChainsQuality-Adjusted Life YearsMaleFemaleDecision TreesDisease ProgressionModels, Economic

Stichwörter der Autor:innen

Markov modelThe Netherlandsartificial intelligencecost-effectivenesshealth economic modelprimary open-angle glaucomascreening

Autor:innen und Institutionen

  • Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands. Electronic address: boverhof@eshpm.eur.nl.
  • Institute for Medical Technology Assessment, Rotterdam, The Netherlands.
  • Rotterdam Ophthalmic Institute, the Rotterdam Eye Hospital, Rotterdam, The Netherlands.
  • Ophthalmology, Erasmus Medical Center, Rotterdam, The Netherlands; Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Ophthalmology, Erasmus Medical Center, Rotterdam, The Netherlands; Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands; Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands; Institute…
  • Ophthalmology, Erasmus Medical Center, Rotterdam, The Netherlands.

Förderung

  • Oogfonds

Zitieren

APA

Boverhof, B. J., Corro Ramos, I., Vermeer, K. A., de Vries, V. A., Klaver, C. C. W., Ramdas, W. D., Lemij, H. G., & Rutten-van Mölken, M. (2025). The Cost-Effectiveness of an Artificial Intelligence-Based Population-Wide Screening Program for Primary Open-Angle Glaucoma in The Netherlands. Value in Health, 28(9), 1317-1326. https://doi.org/10.1016/j.jval.2025.06.006

Vancouver

Boverhof BJ, Corro Ramos I, Vermeer KA, de Vries VA, Klaver CCW, Ramdas WD, et al. The Cost-Effectiveness of an Artificial Intelligence-Based Population-Wide Screening Program for Primary Open-Angle Glaucoma in The Netherlands. Value in Health. 2025;28(9):1317-1326. doi:10.1016/j.jval.2025.06.006

BibTeX
@article{Boverhof2025,
  author = {Boverhof, Bart-Jan and Corro Ramos, Isaac and Vermeer, Koen A and de Vries, Victor A and Klaver, Caroline C W and Ramdas, Wishal D and Lemij, Hans G and Rutten-van Mölken, Maureen},
  title = {The Cost-Effectiveness of an Artificial Intelligence-Based Population-Wide Screening Program for Primary Open-Angle Glaucoma in The Netherlands},
  journal = {Value in Health},
  year = {2025},
  volume = {28},
  number = {9},
  pages = {1317--1326},
  doi = {10.1016/j.jval.2025.06.006}
}
Kostenlos starten →